NLRP3 and neoplasm: Furthermore, although new-generation inhibitors demonstrate greater specificity for the NLRP3 complex, they still lack tumor-selective activity, raising concerns about off-target effects in tissues with physiological inflammasome functions (Zahid et al., 2019).